A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

By sjmartinez • February 15, 2024

Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2024 Feb 15. doi: 10.2217/fon-2023-0859. Epub ahead of print. PMID: 38357801.

Tags: encorafenib plus binimetinib, Hematology/Oncology, Non-small cell lung cancer, PHAROS, plain language summary

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Konecny GE, Lim PC, Santin AD, Gilbert L, Alvarez Secord A, Bessette P, Matulonis UA, Sen J, Hong J, Lytle GE, Bako E, Spunt SL,[...]

Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply

O'Reilly EM, Wolpin BM, Wainberg ZA. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2026 Oct 22;395(16):1662. doi: 10.1056/NEJMc2611022. PMID: 42906097.

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Leshchiner I, Medford AJ, Cha J, Kiedrowski LA, Niemierko A, Keenan JC, Dai CS, Spring LM, Moy B, Wander SA, Vidula N, Isakoff SJ, Juric[...]